HNHacker News
TopNewBestAskShowJobs

rgejman

672 karma · joined December 26, 2009

http://ron.gejman.com [ my public key: https://keybase.io/rgejman; my proof: https://keybase.io/rgejman/sigs/jXEYtNnNbzvxR-zVpC8bW7XBAdDKvlfIRh2qhvWA3w8 ]
submissionscomments
rgejman··on Scientists in Germany, Peru and Taiwan to Lose Access to Elsevier Journals
I bet the nonchalance here has a lot to do with Sci-Hub. Although supplementary materials are still a problem there.
rgejman··on Freud’s Discontents
Outstanding essay on why Freud has faded from his ultimate cultural and scientific pedestal -- and why and other grand theorists are not relevant today. I agree with the author that "The grand theories of an earlier age offered us an ability to look at the intersections between the self, society, and history; in comparison, their replacements look not just intellectually meek but politically unpromising."

On the other hand, the potency of well defined, minimal theories is unarguable.

rgejman··on Congressman calls for probe into Valeant’s pricing of lead poisoning drug
This is a very old drug. All of its relevant properties have been studied for decades.
rgejman··on Congressman calls for probe into Valeant’s pricing of lead poisoning drug
The real disgusting thing here is that EDTA, the heavy metal chelator, is one of the most commonly used chemicals in molecular biology. It costs very little to synthesize and is very stable when stored at room temp. In fact, it can be stored as a powder and reconstituted just-in-time to increase stability. There really is no reason this drug should cost more than a few dollars.
rgejman··on First human Crispr gene-editing trial gets early approval
Maybe. We haven't been doing this long enough to know. T cells can divide into a T "memory" type, but I'm not sure if CAR-T cells do this.
rgejman··on First human Crispr gene-editing trial gets early approval
T cells proliferate when they see their target antigen. This technology is being used without CRISPR in a number of clinical trials. See here: http://www.cancer.gov/about-cancer/treatment/research/car-t-...
rgejman··on Game of Genomes
Yeah, but you can often derive the original FASTQ file from the BAM file anyway so it's like raw data PLUS.
rgejman··on Game of Genomes
Generally I thought this was a great piece. I was a little annoyed that he kept referring to "BAM" files as holding his genomic information. e.g.: "He wanted to get his own BAM file and study it."

BAM is just a format that describes the way that short chunks of DNA are aligned to a reference file of other DNA. It would be a BAM file whether you are talking about someone's genome or an experiment where the readout was a sequencing assay.

To hear how off that sounds, consider the following: "He wanted to get his own m4a file to listen to it." "She wanted to get her own xlsx file to calculate her expenses"

Perhaps its a small gripe, but why not just say "raw data" or "genomic sequence" either of which would be more accurate and not cause some of us to cringe!

rgejman··on NYC subway math
Isn't the last graph showing a poisson distribution, which is exactly what you expect for situations like "waiting for a train that comes on a schedule"?
rgejman··on You hear a voice in your head when you're reading, right?
I don't hear a voice in my head when I read. When I try to read that paragraph, I can't get past the 4th word without an uncomfortable mental pause. In order to continue reading I do have to "hear" it as I'm reading it. How did you come up with this?
rgejman··on Genetically modified mosquitoes used to fight dengue, zika in Brazil
NO. The article is talking about releasing sterile mosquitoes. This is a chronic intervention in the sense that you need to continue releasing sterile mosquitoes over time in order to keep populations low. The gene drive technology is a one-shot deal: you release a few mosquitos and a few generations later none of them can be infected with malaria.
rgejman··on Genetically modified mosquitoes used to fight dengue, zika in Brazil
Gene drives do not have to be used to eradicate mosquitos (although they can be used that way). They can be used to spread malaria resistance genes to mosquitoes, thereby rendering mosquito populations immune to malaria infection.

http://www.pnas.org/cgi/doi/10.1073/pnas.1521077112

rgejman··on Genetically modified mosquitoes used to fight dengue, zika in Brazil
I think it's only a matter of time before someone decides to release a gene-drive mosquito into the wild: https://en.wikipedia.org/wiki/Gene_drive
rgejman··on “Heroes of CRISPR” Disputed
I wonder if the patent war over CRISPR will ever be relevant, given the discovery of Cpf1 and other Cas9-like molecules http://www.cell.com/abstract/S0092-8674(15)01200-3

Does anyone know if the existing CRISPR patents are specific to Cas9 or do they cover any RNA-guided endonucleases?

rgejman··on The sad economics of being famous on the internet
How is this different than the traditional arts and entertainment fields? Most singers, song writers, painters, sculptors, writers, etc also struggle their whole life to make a living. Just because your art is digital and you can reach hundreds of thousands of people at the click of a button doesn't mean that you will become rich overnight. Sure we need new revenue models for content on the Internet--but my prediction is that they will lead to a lot fewer people watching content (much less paying for it). Not to mention that if your fan base is comprised of 13 year olds who need to ask their parents for a credit card every time, you can't make much money off of them.
rgejman··on L-Theanine Experiment (1 Month)
I don't think your platform is exempt from the "common rule" requirement to obtained oversight from an IRB.

The fact that L-theanine is obtainable over the counter is not material. If you study the effects of aspirin on cancer outcomes, you must still obtain consent and IRB review.

A supplements distributor that records whether supplements work is still engaging in human subjects research.

rgejman··on L-Theanine Experiment (1 Month)
As an aside: it's a cool idea and worth trying--but you are going to need to make sure that you are compliant with this country's laws regarding the responsible conduct of human subjects research!
rgejman··on L-Theanine Experiment (1 Month)
This website almost certainly violates FDA rules on human subject experimentation because it collects data on the effect of a drug on human subjects. I would stop working on this project until you have advisors (and lawyers) who have experience with regulatory oversight from the FDA. At the bare minimum you are going to need (a) procedures to gain informed consent from trial enrollees and (b) an Institutional Review Board (IRB) to sign off on your trial. Depending on the drug, you might also need an FDA waiver to conduct the trial.

The PhD student (Rob Wagner) listed in the about section should have had at least one course on the responsible conduct of research. This course is required for most (all?) scientists working under a training or research grant from the NIH. Design and implementation of clinical trials--along with the ethical and legal issues involves--is standard fare for these courses for precisely this reason!

rgejman··on The Glacial Pace of Scientific Publishing
That's fair, but she's writing an editorial in FASEB, which is the Federation of American Societies for Experimental Biology journal :).
rgejman··on The Glacial Pace of Scientific Publishing
I think this is an unfair characterization of her editorial. She did not get to her position by getting mediocre papers published in good places! She is just asking authors to be honest about whether their findings are of sufficient importance/impact to be published in one of the top journals. I have seen many many colleagues run the journal mill, aiming as high as possible for as long as possible, just like she describes. It indeed wastes time and clogs up the system!
rgejman··on The Glacial Pace of Scientific Publishing
You probably couldn't pay them enough to get the job done faster. Any amount you could pay them would probably be insulting compared to the # of hours it takes to properly review a paper. Also, we don't really want to increase the cost of submission/publication/journal subscriptions any more than necessary.
rgejman··on The Glacial Pace of Scientific Publishing
In the biomedical sciences most publications DO NOT end up on preprint servers before being peer-reviewed and accepted. Therefore most stories are "done" a year or more before they are published anywhere. Sometimes they are presented at conferences, but often only once the paper is in submission.
rgejman··on Coca-Cola Funds Scientists Who Shift Blame for Obesity Away from Bad Diets
Unfortunately, < 40% of trials on ClinicalTrials.gov report results after completion :(. http://www.nejm.org/doi/full/10.1056/NEJMsa1409364
rgejman··on Twitter’s stock falls toward IPO-level prices
I predict that Twitter revenue will grow as iOS 9 is released. iOS 9 will cause mobile advertising to undergo a paradigm shift as app-centered advertising becomes more important than website-based advertising. This will lead to increased ad dollar spending on Twitter.
rgejman··on Show HN: FDA Drug Reactions
"% of total reports by age" -- are you adjusting for the # of people of each age taking the drug?
rgejman··on The Data Science Handbook
Is there a sample chapter? It's hard to know if I want to purchase it without knowing anything about how the book is written or whether it tried to achieve its purpose.
rgejman··on Notable Labs (YC W15): Personalized Medical Testing for Brain Cancer Patients
No doubt GBM patients are in major need of novel therapeutic options. My major concern with this kind of a project is that the drugs may end up killing patients faster than the tumor will. For instance, some drugs are known to inhibit tumor growth AND immune cell signaling because they target shared pathways. The tumor can out-grow this interference; the immune system cannot. You will not know if your interventions are helping or hurting the people you are treating until you do a properly controlled study.

Second: in my experience, one of the major problems with screens for synergistic (or additive) therapies is multiple testing. If you test 100 compounds (10,000 combinations), a large number of combinations will appear to work by chance. Do you have a secondary screening approach to reduce false positives?

rgejman··on Antibiotics targeting mitochondria kill cancer stem cells of several tumor types
General thoughts: Cancer patients—in particular those with blood cancers—are routinely immunocompromised and put on antibiotics. Any potent effects would almost certainly have been realized by now. There are a lot of people who have made their careers by tracking what therapies work and which don't—and that includes controlling for "confounders" like those given antibiotics, etc.

Oncotarget isn't a bad journal—and this is certainly a good idea which may have applications we can't quite imagine yet. But it's unlikely to be a potent cancer therapy.

rgejman··on Apple Reports Record First Quarter Results
Did AppleInsider rip off your numbers? http://appleinsider.com/articles/15/01/28/by-the-numbers-app...
rgejman··on San Diego Researcher Crowdfunding Patent-Free Cancer Drug
These philanthropic organizations almost always have either (a) committees made up of scientists that decide where the money should be allocated (e.g. HHMI) or (b) donate to institutions which then dole out money internally as project grants that are vetted by other scientists.

Philanthropic organizations don't generally just hand out money to the person who makes the flashiest video.

← PreviousPage 3 of 5Next →